Jordana B Cohen1,2, Jayme E Locke3, Brittany Shelton3, Rhiannon D Reed3, Margaux Mustian3, Paul MacLennan3, Kimberly A Forde2,4, Peter P Reese1,2, Deirdre Sawinski1,2. 1. Renal Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 2. Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Department of Surgery, University of Alabama at Birmingham Comprehensive Transplant Institute, Birmingham, Alabama. 4. Gastroenterology Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Abstract
BACKGROUND: Despite a survival benefit from transplantation and acceptable outcomes, patients with human immunodeficiency virus (HIV+) face barriers to kidney transplantation. Little is known about the acceptance or decline of organ offers on their behalf because waitlist registry data do not include HIV serostatus. METHODS: We performed a retrospective cohort study using match run data from the Organ Procurement and Transplantation Network, including every kidney offer from May 1, 2007, to July 3, 2013. HIV and hepatitis C virus (HCV) serostatus were obtained by merging the match run with clinical data from a large dialysis provider. We used Cox proportional hazards modeling to evaluate differences in time to the first organ offer and to transplantation. A total of 35 646 uninfected, 2213 HCV+, 418 HIV+, and 71 HIV+/HCV+ candidates received organ offers during the study period. RESULTS: Compared to uninfected candidates, HIV+ candidates had a significantly lower likelihood of receiving a first offer (adjusted hazard ratio [aHR] 0.88, 95% confidence interval [CI] 0.79-0.99) and undergoing transplantation (aHR 0.82, 95% CI: 0.68-0.98) after receiving a first offer; HCV+ candidates had a similar likelihood of receiving a first offer (aHR 0.98, 95% CI: 0.92-1.03) and greater likelihood of transplantation after receiving a first offer (aHR 1.23, 95% CI: 1.12-1.36). CONCLUSIONS: HIV+ candidates had a significantly longer wait until their first organ offer and to transplantation. Efforts to increase their access to transplantation are needed.
BACKGROUND: Despite a survival benefit from transplantation and acceptable outcomes, patients with human immunodeficiency virus (HIV+) face barriers to kidney transplantation. Little is known about the acceptance or decline of organ offers on their behalf because waitlist registry data do not include HIV serostatus. METHODS: We performed a retrospective cohort study using match run data from the Organ Procurement and Transplantation Network, including every kidney offer from May 1, 2007, to July 3, 2013. HIV and hepatitis C virus (HCV) serostatus were obtained by merging the match run with clinical data from a large dialysis provider. We used Cox proportional hazards modeling to evaluate differences in time to the first organ offer and to transplantation. A total of 35 646 uninfected, 2213 HCV+, 418 HIV+, and 71 HIV+/HCV+ candidates received organ offers during the study period. RESULTS: Compared to uninfected candidates, HIV+ candidates had a significantly lower likelihood of receiving a first offer (adjusted hazard ratio [aHR] 0.88, 95% confidence interval [CI] 0.79-0.99) and undergoing transplantation (aHR 0.82, 95% CI: 0.68-0.98) after receiving a first offer; HCV+ candidates had a similar likelihood of receiving a first offer (aHR 0.98, 95% CI: 0.92-1.03) and greater likelihood of transplantation after receiving a first offer (aHR 1.23, 95% CI: 1.12-1.36). CONCLUSIONS:HIV+ candidates had a significantly longer wait until their first organ offer and to transplantation. Efforts to increase their access to transplantation are needed.
Authors: Alison G Abraham; Keri N Althoff; Yuezhou Jing; Michelle M Estrella; Mari M Kitahata; C William Wester; Ronald J Bosch; Heidi Crane; Joseph Eron; M John Gill; Michael A Horberg; Amy C Justice; Marina Klein; Angel M Mayor; Richard D Moore; Frank J Palella; Chirag R Parikh; Michael J Silverberg; Elizabeth T Golub; Lisa P Jacobson; Sonia Napravnik; Gregory M Lucas Journal: Clin Infect Dis Date: 2014-11-18 Impact factor: 9.079
Authors: Jayme E Locke; Sally Gustafson; Shikha Mehta; Rhiannon D Reed; Brittany Shelton; Paul A MacLennan; Christine Durand; Jon Snyder; Nicholas Salkowski; Allan Massie; Deirdre Sawinski; Dorry L Segev Journal: Ann Surg Date: 2017-03 Impact factor: 12.969
Authors: Peter G Stock; Burc Barin; Barbara Murphy; Douglas Hanto; Jorge M Diego; Jimmy Light; Charles Davis; Emily Blumberg; David Simon; Aruna Subramanian; J Michael Millis; G Marshall Lyon; Kenneth Brayman; Doug Slakey; Ron Shapiro; Joseph Melancon; Jeffrey M Jacobson; Valentina Stosor; Jean L Olson; Donald M Stablein; Michelle E Roland Journal: N Engl J Med Date: 2010-11-18 Impact factor: 91.245
Authors: Jayme E Locke; Shikha Mehta; Rhiannon D Reed; Paul MacLennan; Allan Massie; Anoma Nellore; Christine Durand; Dorry L Segev Journal: J Am Soc Nephrol Date: 2015-03-19 Impact factor: 10.121
Authors: Jayme E Locke; Shikha Mehta; Deirdre Sawinski; Sally Gustafson; Brittany A Shelton; Rhiannon D Reed; Paul MacLennan; Charlotte Bolch; Christine Durand; Allan Massie; Roslyn B Mannon; Robert Gaston; Michael Saag; Turner Overton; Dorry L Segev Journal: Clin J Am Soc Nephrol Date: 2017-02-23 Impact factor: 8.237
Authors: D Sawinski; C M Wyatt; L Casagrande; P Myoung; I Bijan; E Akalin; B Schröppel; G DeBoccardo; V Sehgal; R Dinavahi; S Lerner; S Ames; J Bromberg; S Huprikar; M Keller; B Murphy Journal: Am J Transplant Date: 2009-05-13 Impact factor: 8.086
Authors: Deirdre Sawinski; Kimberly A Forde; Kevin Eddinger; Andrea B Troxel; Emily Blumberg; Pablo Tebas; Peter L Abt; Roy D Bloom Journal: Kidney Int Date: 2015-03-25 Impact factor: 10.612
Authors: Shanti M Seaman; Sarah E Van Pilsum Rasmussen; Anh Q Nguyen; Samantha E Halpern; Susan You; Madeleine M Waldram; Saad K Anjum; Mary Grace Bowring; Abimereki D Muzaale; Darin B Ostrander; Diane Brown; Allan B Massie; Aaron A R Tobian; Macey L Henderson; Faith E Fletcher; Burke Smith; Ada Chao; Nishita Gorupati; Katya Prakash; Saima Aslam; Dong H Lee; Varvara Kirchner; Timothy L Pruett; Ghady Haidar; Kailey Hughes; Maricar Malinis; Sonya Trinh; Dorry L Segev; Jeremy Sugarman; Christine M Durand Journal: J Acquir Immune Defic Syndr Date: 2020-09-01 Impact factor: 3.771
Authors: Christine M Durand; Wanying Zhang; Diane M Brown; Sile Yu; Niraj Desai; Andrew D Redd; Serena M Bagnasco; Fizza F Naqvi; Shanti Seaman; Brianna L Doby; Darin Ostrander; Mary Grace Bowring; Yolanda Eby; Reinaldo E Fernandez; Rachel Friedman-Moraco; Nicole Turgeon; Peter Stock; Peter Chin-Hong; Shikha Mehta; Valentina Stosor; Catherine B Small; Gaurav Gupta; Sapna A Mehta; Cameron R Wolfe; Jennifer Husson; Alexander Gilbert; Matthew Cooper; Oluwafisayo Adebiyi; Avinash Agarwal; Elmi Muller; Thomas C Quinn; Jonah Odim; Shirish Huprikar; Sander Florman; Allan B Massie; Aaron A R Tobian; Dorry L Segev Journal: Am J Transplant Date: 2020-08-08 Impact factor: 9.369
Authors: Shanti Seaman; Diane Brown; Ann Eno; Sile Yu; Allan B Massie; Aaron A R Tobian; Christine M Durand; Dorry L Segev; Albert W Wu; Jeremy Sugarman Journal: J Patient Rep Outcomes Date: 2021-03-18
Authors: Sarah E Van Pilsum Rasmussen; Shanti Seaman; Morgan A Johnson; Karen Vanterpool; Diane M Brown; Aaron A R Tobian; Timothy Pruett; Varvara Kirchner; Faith E Fletcher; Burke Smith; Sonya Trinh; Dorry L Segev; Christine M Durand; Jeremy Sugarman Journal: Transplant Direct Date: 2021-08-06